市场消息:美国食品药品监督管理局(FDA)批准Ozempic作为唯一一种GLP-1受体激动剂,以降低2型糖尿病和慢性肾病

美港电讯
29 Jan

市场消息:美国食品药品监督管理局(FDA)批准Ozempic作为唯一一种GLP-1受体激动剂,以降低2型糖尿病和慢性肾病成人患者严重肾病恶化及心血管死亡的风险。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10